

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number  
**WO 02/11694 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K 9/00**
- (21) International Application Number: **PCT/EP01/08978**
- (22) International Filing Date: **2 August 2001 (02.08.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
**100 38 571.0** **3 August 2000 (03.08.2000)** **DE**
- (71) Applicant (for all designated States except US): **KNOLL GMBH [DE/DE]; Knollstrasse, 67061 Ludwigshafen (DE).**
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **ROSENBERG, Jörg [DE/DE]; Bruchstrasse 29, 67158 Ellerstadt (DE). BERNDL, Gunther [DE/DE]; Am Dörrling 7, 67273 Herxheim (DE). NEUMANN, Jörg [DE/DE]; Paul-Münch-Strasse 12, 67117 Limburgerhof (DE). BREITENBACH, Jörg [DE/DE]; Hans-Sachs-Ring 95A, 68199 Mannheim (DE).**
- (74) Agents: **KINZEBACH, Werner et al.; Reitstötter, Kinzebach & Partner, Sternwartstrasse 4, 81679 München (DE).**
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**
- (84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN THE ORAL CAVITY IN THE TREATMENT OF MYKOSES**

(57) Abstract: **A solid dosage form for application in the oral cavity, comprising a poorly bioavailable pharmaceutical active ingredient dispersed in a pharmaceutically acceptable matrix.**

**WO 02/11694 A2**

Compositions and dosage forms for application in the oral cavity in the treatment of mykoses

5 The present invention relates to solid pharmaceutical dosage forms for application in the oral cavity, comprising a formulation of an antimycotic active ingredient in the form of a solid dispersion of the active ingredient in a pharmaceutically acceptable matrix.

10

The invention also relates to the use of such formulations for manufacture of a medicament for application in the oral cavity in the treatment of mycoses, especially mycosis caused by *Candida albicans*.

15

Furthermore the invention relates to a process for the manufacture of such formulations.

Since administration of drugs in all regions from the neck up  
20 avoids first-pass metabolism, administration in the oral cavity seems to be a very efficacious way to deliver systemic drugs.

This is especially important in the case of pharmaceutically active ingredients which show poor bioavailability due to first  
25 pass metabolism and/or poor water-solubility.

In the treatment of oral mykoses it is particularly advantageous to provide for relatively high local concentrations of the active ingredient in the oral cavity.

30

Itraconazol, ( $\pm$ )-cis-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-yl-methyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one, and its pharmaceutically acceptable salts, is known as  
35 an effective active ingredient for oral, parenteral and topic treatment of various types of mykoses. Predominantly, itraconazol is administered orally because of its tendency of extensive tissue distribution.

40 However, since itraconazole is almost insoluble in water (less than 1  $\mu\text{g/ml}$ ), bioavailability is a major problem.

Many attempts have been made to improve the bioavailability of almost insoluble drug compounds. Among them, solid dispersions of  
45 drug and hydrophilic polymers have been suggested to enhance the solubility of the drug.

WO 97/44014 discloses particles, comprising formulations of itraconazole and water-soluble polymers, said formulations being obtained by melt-extrusion, preferably using hydroxypropyl methylcelluloses as water-soluble polymers. The oral dosage forms disclosed in that document show a remarkably lower food effect.

According to WO 95/31178 mucoadhesive emulsion formulations, comprising itraconazole and cyclodextrins, are useful in the treatment of vaginal infections.

10

The object of the present invention is to provide formulations and dosage forms for application in the oral cavity for the treatment of mykoses, especially mykoses of the oral cavity.

15 Formulations according to the present invention comprise an antimycotic active ingredient in the form of solid dispersions of the active ingredient in a pharmaceutically acceptable matrix, particularly molecular dispersions of the active ingredient in the polymer.

20

Antimycotic active ingredients are preferably compounds with a solubility in water (according to the United States Pharmacopeia XXIII) such that more than 1000 parts of solvent, more preferably more than 10.000 parts of solvent are needed for one part of

25 solute.

A preferred active ingredient is the above-identified itraconazole. Other suitable active ingredients are saperconazole, ketoconazole or fluconazole.

30

One preferred embodiment of the invention relates to lozenges.

Another preferred embodiment of the invention relates to solid dosage forms comprising mucoadhesive polymers, preferably tablets for sublingual or buccal application. Tablets for gingival or palatal application are also within the scope of the invention.

35

According to the present invention the active ingredient is homogeneously dispersed in a pharmaceutically acceptable matrix.

40 Preferably, the solid dispersion is in the form of a molecular dispersion of the active ingredient, i.e. a so-called "solid solution". The term "solid solution" is familiar to the skilled person.

45

The pharmaceutically acceptable matrix is based on polymers or low-molecular excipients normally used as fillers for tableting such as for instance sugars or sugar alcohols as matrix building components.

5

Suitable polymers are selected from the group consisting of:

Cellulose derivatives, e.g. alkylcelluloses,  
hydroxyalkylcelluloses, hydroxyalkyl alkylcelluloses.

10

Acrylic polymers of the Eudragit® type like copolymers based on methacrylic acid and methacrylic acid methyl ester

Homo- and copolymers of N-vinylpyrrolidone with Fikentscher K  
15 values in the range of from 17 to 100, vinylacetate being a preferred comonomer, e.g. a copolymer obtained from 60 % b.w. of n-vinylpyrrolidone and 40 % b.w. of vinyl acetate

Polyethylene glycols with molecular weights in the range of from  
20 6000 to 100.000 Dalton, polyoxyethylene polyoxypropylene block copolymers

Suitable low-molecular weight matrix components are selected from the group consisting of sugars and sugar alcohols, for example  
25 sorbitol, xylitol, maltitol, erythritol, mannitol, isomalt and the like.

In the case of formulations for lozenges sugar alcohols are preferred matrix components.

30

The amount of matrix building components used in the formulations may range from 5 to 90 % b.w., preferably 10 to 70 % b.w., more preferably 10 to 50 % b.w..

35 Notwithstanding the fact that some of the aforementioned matrix building polymers show mucoadhesive properties, such polymers are only used optionally in formulations for lozenges. However, formulations or finished dosage forms for buccal, sublingual, gingival or palatinal application preferably comprise such  
40 mucoadhesive polymers, optionally in combination with other polymers. Such mucoadhesive polymers are selected from the group consisting of:

Acrylic copolymers of the Eudragit® type

45 Crosslinked polyacrylics (CTFA name: Carbomer)

Sodium carboxymethylcellulose

Tragant gum

Poly(methyl)vinylether-co- maleic acid anhydride  
Alkylcelluloses, e.g. methylcellulose  
Alginates like sodium alginate  
Polyvinylpyrrolidone

5

According to one embodiment of the invention the mucoadhesive polymer is incorporated in the melt formulation.

According to another embodiment of the invention the solid  
10 dispersions of the active ingredient obtained by melt formulation are mixed with one or more mucoadhesive polymers and subsequently processed to finished dosage forms (tablets). For example, 10 to 70 % b.w. of a solid dispersion of the active ingredient in a pharmaceutically acceptable matrix as outlined above can be mixed  
15 with 30 to 90 % b.w. of mucoadhesive polymers.

In addition the matrix formulations or finished dosage forms may contain conventional pharmaceutical ancillary substances, for example extenders such as silicates or diatomaceous earth, mould  
20 releasers such as stearic acid or salts thereof, wetting agents, preservatives, disintegrants, absorbants, colorants, and the like (cf., for example H. Sucker et al. Pharmazeutische Technologie, Thieme Verlag, Stuttgart 1978). The ancillary substances must be thermally stable at the temperature used in the process for  
25 manufacture used here.

Preferred ancillary substances are flavourings and artificial sweeteners for masking the sometimes unpleasant taste of the drug compounds. Suitable artificial sweeteners are for instance sodium  
30 saccharinate, aspartame, neohesperidine or acesulfame, preferably acesulfame or mixtures comprising acesulfame and aspartame. These sweeteners are used in amounts of from 0.05 to 1.0 % b.w., preferably 0.2 to 0.5 to 0.5 b.w.. Another preferred class of sweeteners are sugar alcohols, preferably xylitol, maltitol or  
35 isomalt. In case sugar alcohols are used as matrix components additional sweeteners normally are not needed. Sugar alcohols can be used in amounts of from 2 to 60 % b.w., preferably 5 to 40 % b.w..

40 A preferred method for manufacturing the formulations and finished dosage forms of the present invention is a melt-extrusion process. A preferred apparatus for such process is an extruder equipped with one or more screws, preferably a twin screw extruder. The mixtures comprising all the components of the  
45 pharmaceutical formulations can be processed at temperatures in the range of from 50 to 180°C, preferably 80 to 160°C. Preferably

the process is carried out in the absence of solvents, e.g. water or organic solvents.

In addition, small amounts of crosslinked polyvinylpyrrolidone  
5 (Kollidon® CL) can be used as taste masking agent.

The molten pharmaceutical mixtures are extruded and the still thermoplastic mass is subsequently shaped. Shaping can take place e.g. by hot cutting the extruded strands to give granules or  
10 pellets which can be pressed to tablets in a conventional way.

A preferred method for shaping is a calendering process as described for instance in EP-A 240 906 which comprises that the still deformable extrudate is fed between the surfaces of two  
15 counter-rotating molding rolls, the surfaces of said rolls having opposed depressions, whereby, separate tablets having the shape of such depressions are formed. The calender and molding rolls useful for the present invention can be cooled or heated per se and the optimum surface temperature of the rolls for the relevant  
20 processing step can be adjusted in this way.

The invention also relates to specifically shaped dosage forms for those formulations comprising mucoadhesive polymers.

25 Preferred dosage forms are lenticular or semi-lenticular tablets which can be round or oval and with an angle  $\alpha$  (see Fig.) between the cross-sectional plane of the tablet and the convex tablet body (tangential area) of less than  $90^\circ$ . Fig. 1 and 2 show such an oval lenticular tablet with a tablet length (a), tablet width (b)  
30 and thickness (c). Fig. 3 and 4 show a round lenticular tablet with a diameter (d) and a thickness (c).

For instance, oval lozenges can have a length of from 10 to 20 mm, a width of from 6 to 12 mm and a thickness of from 3 to  
35 12 mm. Round lozenges can have a diameter of from 5 to 14 mm and a thickness of from 3 to 10 mm.

In the case of semi-lenticular tablets the lower half of the tablet is essentially planar. Fig. 5 shows a round  
40 semi-lenticular tablet, Fig. 6 an oval semi-lenticular tablet. Such tablet forms are especially well suited for buccal, gingival, sublingual or palatal application, since they cause little irritation when positioned in the oral cavity. Also, in view of the low tablet weight generally accepted for buccal forms  
45 (up to 200 mg per tablet) the ratio of surface to tablet volume is particularly advantageous because of the large surface. Such tablets can have a length of from 3 to 10 mm, a width of from 2

to 6 mm, a thickness of from 1.5 to 5 mm (oval forms) or a diameter of from 3 to 10 mm and a thickness of from 1.5 to 5 mm (round forms). Round semi-lenticular tablets are preferred.

- 5 Such dosage forms can be manufactured using a calendering process as described above. In the case of semi-lenticular tablets only one of the calender rolls is having depressions, whereas the other roll is planar.
- 10 Another method for manufacturing semi-lenticular tablets is by shaping the melt with the aid of a rotating perforated roll into drops which are subsequently solidified by cooling.

The dosage forms obtained according to the present invention are  
15 particularly useful in the treatment of oral mykoses.

Surprisingly, the solid solutions according to the present invention deliver the active ingredient without substantial recrystallization in an aqueous environment like the oral cavity,  
20 thus achieving sufficient plasma levels.

Therefore, the dosage forms according to the invention are useful in the treatment of diseases of the oral cavity by delivering high local concentrations as well as in systemic treatment.

25

#### Examples

##### General Method

- 30 Tablets were produced starting from molten mixtures of the components and extruding said mixtures using a twin screw extruder (Leistritz Micro 18). The still thermoplastic extrudate was calendered as described in EP-A 240 906 to give oval lozenges of 17,4 mm length, 8.5 mm width and 4.7 mm thickness with a mean  
35 tablet weight of 450 mg.

The dissolution rates were determined according to the USP-paddle model at 50 rpm. 37°C, no change pH 1.0 (0.5 % SDS).

- 40 The formation of solid solutions was determined by DSC (Differential Scanning Calorimetry) measurements using a Mettler TA 4000 System.

45

## Example 1

Itraconazol	20 % b.w.
Hydroxypropylcellulose	80 % b.w.
5 Melt temperature:	133°C
Dissolution: 95 % after 8 h	

## Example 2

10 Itraconazol	20 % b.w.
Hydroxypropylcellulose	70 % b.w.
Hydroxypropylmethylcellulose	10 % b.w.
Melt temperature:	135°C
Dissolution: 77 % after 8 h	

15

## Example 3

Itraconazol	20 % b.w.
N-vinylpyrrolidone vinylacetate	
20 Copolymer (VP/Vac 60/40)	60 % b.w.
Hydroxypropylcellulose	10 % b.w.
Melt temperature:	152°C
Dissolution: 93 % after 8 h	

25

30

35

40

45



## Claims

1. A solid dosage form for application in the oral cavity,  
5 comprising a poorly bioavailable pharmaceutical active ingredient dispersed in a pharmaceutically acceptable matrix.
2. A dosage form according to claim 1, wherein the active ingredient is molecularly dispersed in the matrix.
- 10 3. A dosage form according to claims 1 or 2, wherein the solubility of the pharmaceutically active ingredient in water is such that more than 10.000 parts of water are needed for one part of active ingredient.
- 15 4. A dosage form according to any of claims 1 to 3, comprising itraconazole as active ingredient.
- 20 5. A dosage form according to any of the claims 1 to 4 in the form of a lozenge.
6. A dosage form according to claim 5 comprising one or more sugar alcohols as matrix components.
- 25 7. A dosage form according to any of the claims 1 to 4, comprising mucoadhesive polymers.
8. A dosage form according to claim 7, wherein the mucoadhesive polymer is a crosslinked polyacrylic acid.
- 30 9. A dosage form according to claim 7, wherein the mucoadhesive polymer is a poly(meth)acrylate.
10. A dosage form according to any of the claims 7 to 9 in  
35 the form of a tablet for buccal, sublingual, gingival or palatinal application.
11. A dosage form according to claim 10, consisting of lenticular or semi-lenticular shaped tablets.
- 40 12. A dosage form according to any of claims 1 to 11, obtained by a melt-extrusion process.

13. The use of dosage forms according to any of claims 1 to 12 for the manufacture of a medicament for the treatment of mykoses.

5 14. The use according to claim 13 for the manufacture of a medicament for the treatment of oral mykoses.

10

15

20

25


30

35


40

45

1 / 4




*Fig. 1*




*Fig. 2*

2/4




*Fig. 3*




*Fig. 4*

3 / 4



*Fig. 5*

4 / 4



*Fig. 6*

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number  
**WO 02/11694 A3**

- (51) International Patent Classification<sup>7</sup>: **A61K 9/20**,  
A61P 31/10
- (21) International Application Number: PCT/EP01/08978
- (22) International Filing Date: 2 August 2001 (02.08.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
100 38 571.0 3 August 2000 (03.08.2000) DE
- (71) Applicant (for all designated States except US): **KNOLL GMBH** [DE/DE]; Knollstrasse, 67061 Ludwigshafen (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **ROSENBERG, Jörg** [DE/DE]; Bruchstrasse 29, 67158 Ellerstadt (DE). **BERNDL, Gunther** [DE/DE]; Am Dörrling 7, 67273 Herxheim (DE). **NEUMANN, Jörg** [DE/DE]; Paul-Münch-Strasse 12, 67117 Limburgerhof (DE). **BREITENBACH, Jörg** [DE/DE]; Hans-Sachs-Ring 95A, 68199 Mannheim (DE).
- (74) Agents: **KINZEBACH, Werner** et al.; Reitstötter, Kinzebach & Partner, Sternwartstrasse 4, 81679 München (DE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:  
25 April 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN THE ORAL CAVITY IN THE TREATMENT OF MYKOSES

(57) Abstract: A solid dosage form for application in the oral cavity, comprising a poorly bioavailable pharmaceutical active ingredient dispersed in a pharmaceutically acceptable matrix.

WO 02/11694 A3

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/08978

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K9/20 A61P31/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, MEDLINE, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 578 315 A (CHIEN YIE W ET AL) 26 November 1996 (1996-11-26)  column 1, line 51 -column 2, line 29 column 6, line 3 column 6, line 67 -column 7, line 4 example 2 claim 1  ---	1-5,7,8, 10,11, 13,14
X	EP 0 250 187 A (JOHNSON & JOHNSON PROD INC) 23 December 1987 (1987-12-23) page 3, line 1 - line 17 page 4, line 4 example 3 claim 1  ---  -/--	1-3,7, 12-14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

22 February 2002

Date of mailing of the international search report

01/03/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Epskamp, S



## INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/EP 01/08978

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 431 915 A (HARVEY BRYCE M ET AL) 11 July 1995 (1995-07-11) column 3, line 14 - line 28 column 4, line 66 - column 5, line 12 column 8, line 52 - line 61 claims 1,18,19 ----	1-3, 12-14
X	WO 97 44014 A (JANSSEN PHARMACEUTICA NV) 27 November 1997 (1997-11-27) cited in the application page 3, line 29 - page 5, line 2 page 6, line 30 - page 7, line 16 page 12, line 22 - line 36 page 14, line 11 - line 13 example 1 claims 1,6 ----	1-14
X	WO 93 18757 A (PFIZER) 30 September 1993 (1993-09-30) example 2 ----	1-3,5,7, 10,11,13
X	EP 0 864 326 A (KNOLL AG) 16 September 1998 (1998-09-16) column 5, line 45,54 column 8, line 3 - line 13 example 1 ----	1-3,5,7, 10-12
A	DE 195 39 359 A (KNOLL AG) 24 April 1997 (1997-04-24) column 1, line 56 - line 67 column 4, line 37 - line 47 column 5, line 22 - line 43 column 7, line 38,47 figure 2 ----	1-14
A	EP 0 240 906 A (BASF AG) 14 October 1987 (1987-10-14) cited in the application page 4, line 15 page 1, line 12 - line 21 page 3, line 1 - line 17 -----	1-14

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/08978

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 5578315	A	26-11-1996	AU	1100295 A	19-06-1995
			EP	0731679 A1	18-09-1996
			JP	9506092 T	17-06-1997
			WO	9515137 A1	08-06-1995
EP 0250187	A	23-12-1987	US	4713243 A	15-12-1987
			AT	95058 T	15-10-1993
			AU	7415587 A	17-12-1987
			CA	1297408 A1	17-03-1992
			DE	3787573 D1	04-11-1993
			DE	3787573 T2	10-02-1994
			EP	0250187 A2	23-12-1987
			GR	870935 A1	19-10-1987
			IE	61785 B	30-11-1994
			JP	2706064 B2	28-01-1998
			JP	8253414 A	01-10-1996
			JP	2540332 B2	02-10-1996
			JP	63019152 A	26-01-1988
			KR	9411243 B1	03-12-1994
			NZ	220573 A	28-11-1989
			PH	24845 A	30-10-1990
			SG	107694 G	28-10-1994
			US	RE33093 E	17-10-1989
			ZA	8704294 A	25-01-1989
US 5431915	A	11-07-1995	NONE		
WO 9744014	A	27-11-1997	AU	722101 B2	20-07-2000
			AU	2956297 A	09-12-1997
			BG	102532 A	26-02-1999
			BR	9706897 A	31-08-1999
			CA	2240161 A1	27-11-1997
			CN	1209740 A	03-03-1999
			CZ	9801885 A3	11-11-1998
			EE	9800304 A	15-02-1999
			WO	9744014 A1	27-11-1997
			EP	0904060 A1	31-03-1999
			HR	970270 A1	30-04-1998
			HU	9901620 A2	28-10-1999
			JP	11509238 T	17-08-1999
			NO	982599 A	19-11-1998
			NZ	330739 A	29-06-1999
			PL	330931 A1	07-06-1999
			SK	84898 A3	10-03-1999
			TR	9801225 T2	23-11-1998
			US	2001007678 A1	12-07-2001
			ZA	9704338 A	19-11-1998
WO 9318757	A	30-09-1993	AT	140625 T	15-08-1996
			AU	3057592 A	21-10-1993
			BR	9207104 A	05-12-1995
			CA	2131089 A1	18-09-1993
			CZ	9402258 A3	18-01-1995
			DE	69212503 D1	29-08-1996
			DE	69212503 T2	12-12-1996
			DK	630237 T3	26-08-1996
			EP	0630237 A1	28-12-1994
			ES	2089581 T3	01-10-1996

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/08978

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9318757	A		FI 944309 A	16-09-1994
			GR 3020666 T3	31-10-1996
			HU 75616 A2	28-05-1997
			IL 105016 A	12-09-1996
			JP 2559206 B2	04-12-1996
			JP 7501829 T	23-02-1995
			MX 9301435 A1	01-10-1993
			NO 943461 A	16-09-1994
			NZ 247168 A	28-03-1995
			WO 9318757 A1	30-09-1993
			US 5529789 A	25-06-1996
			ZA 9301858 A	16-09-1994
EP 0864326	A	16-09-1998	DE 19710009 A1	24-09-1998
			CA 2229650 A1	12-09-1998
			EP 0864326 A2	16-09-1998
			JP 10310518 A	24-11-1998
DE 19539359	A	24-04-1997	DE 19539359 A1	24-04-1997
			AU 705657 B2	27-05-1999
			AU 7491196 A	15-05-1997
			BR 9611239 A	30-03-1999
			CA 2232353 A1	01-05-1997
			CN 1200663 A	02-12-1998
			CZ 9801096 A3	14-07-1999
			WO 9715268 A1	01-05-1997
			EP 0957884 A1	24-11-1999
			HU 9900734 A2	28-10-1999
			JP 11514275 T	07-12-1999
			NO 981795 A	23-04-1998
			SI 9620112 A	31-08-1998
			SK 50698 A3	11-01-1999
			ZA 9608848 A	22-04-1998
EP 0240906	A	14-10-1987	DE 3612211 A1	15-10-1987
			AT 63056 T	15-05-1991
			AU 590697 B2	09-11-1989
			AU 7140087 A	15-10-1987
			CA 1303501 A1	16-06-1992
			CN 87102755 A ,B	28-10-1987
			CS 8702531 A2	13-10-1989
			DE 3769687 D1	06-06-1991
			EP 0240906 A2	14-10-1987
			FI 871538 A ,B,	12-10-1987
			GR 3002559 T3	25-01-1993
			HR 931378 A1	30-04-1996
			HU 55218 A2	28-05-1991
			JP 1977258 C	17-10-1995
			JP 7008293 B	01-02-1995
			JP 62240061 A	20-10-1987
			KR 9405302 B1	16-06-1994
			NO 173588 C	05-01-1994
			PT 84660 A ,B	01-05-1987
			SI 8710590 A8	31-08-1996
			US 4880585 A	14-11-1989
			YU 59087 A1	31-12-1989